Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Letrozole is a nonsteroidal aromatase inhibitor used primarily to treat hormone receptor-positive breast cancer in postmenopausal women. It works by inhibiting the enzyme aromatase, which converts androgens into estrogens in peripheral tissues. By reducing estrogen levels, letrozole slows or stops the growth of certain types of breast cancer cells that require estrogen for proliferation. Letrozole is typically administered orally as a tablet once daily and may be used as first-line therapy, following surgery or radiation, after prior treatment with tamoxifen, or for advanced/metastatic disease. Beyond its primary indication in breast cancer, letrozole has also been studied off-label for conditions such as infertility (ovulation induction), gynecomastia, endometriosis, and other hormonally sensitive tumors[1][4][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on letrozole.